SNCA-targeting siRNAs Prevent Disease Progression in a Synucleinopathy Mouse Model
Time: 11:00 am
day: Conference Day Two
Details:
- Validating efficacy of siRNA in halting dopaminergic neurodegeneration in murine models, mitigating pathological effects associated with SNCA aggregation
- Evaluating the potential of siRNAs in preventing disease progression in synucleinopathy to improve motor function, reduce neuroinflammation or preserve DA neurons
- Preclinical validation of reduced siRNA toxicity to ensure safe treatment of neurodegeneration
